Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Haemonetics CorporationNYSE: HAE

Net Change in Cash · Q1 FY2027 · quarter ended Jun 2026

Net change in cash growth accelerates

Q1 FY2027 net change in cash of $22.06M (cash outflow) rose 59.1% year over year, ahead of the +34.9% change in trailing-twelve-month net change in cash. Sequentially, it fell 81.3% from the prior quarter.

Context

  • Net change in cash amounted to 4.6% of revenue in FY2026, down 4.8 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +59.1% holds above the trailing-twelve-month pace of +34.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$22.06M-81.3% QoQ
Last fiscal yearMar 2026
-$61.32M-147.9% YoY
LTMJun 2026
-$69.51M+34.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.1%——
1 year-147.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2026
(61.32M) USD
Year-over-year change
-147.9%

Net Change in Cash vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 net change in cash of $69.51M is the 4th largest of the 10 companies compared; the peer median is $6.29M.
  • Its year-over-year change of +34.9% is the 4th highest of 10, against a peer median of -72.6%.
  • Net change in cash amounts to 5.1% of revenue for HAE, versus a peer median of 0.9%.
HAE Competitors Peer median
Net Change in Cash for HAE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$208M -294.4%+27.6%5.7%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$175.2M -35.2%+14.7%29.3%
BHCBausch Health Companies Inc.LTM Jun 2026$93.89M -91.6%—0.9%
HAEHaemonetics CorporationLTM Jun 2026$69.51M +34.9%—5.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026$62.27M +513.4%—39.9%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$35.88M +141.3%—1.5%
QDELQuidelOrtho CorporationLTM Mar 2026$13.2M -72.6%—0.5%
WRBYWarby Parker Inc.LTM Jun 2026$6.29M -87.0%—0.7%
ITGRInteger Holdings CorporationLTM Jul 2026$1.76M -84.0%—0.1%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$1.51M +220.4%-20.7%0.6%
Peer median (excluding HAE) $6.29M-72.6%+14.7%0.9%

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income43.38M115.4M117.56M167.68M97.31M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
Deferred Income Tax5.01M4.78M(1.01M)(15.7M)(714K)
Stock-Based Compensation24.36M25.58M28.33M29.64M33.83M
Change in Working Capital(15.18M)25.5M(63.07M)(91.98M)(23.65M)
Accounts Receivables(34.97M)(24.42M)(24.19M)6.96M(14.88M)
Inventory24.31M30.75M(60.06M)(64.7M)47.36M
Accounts Payables039.82M00(16.57M)
Other Working Capital(4.51M)(20.65M)21.19M(34.24M)(39.56M)
Other Non-Cash Items16.95M8.48M2.73M(23.49M)74.74M
Operating Cash Flow172.26M273.06M181.75M181.73M293.22M
Capital Expenditures(96.51M)(110.19M)(38.13M)(39.28M)(32.78M)
Acquisitions (Net)8.14M(2M)(242.35M)(107.62M)1.38M
Purchases of Investments0(33.21M)000
Sales of Investments00000
Other Investing Activities2.02M1.61M(41.91M)(15M)(87.96M)
Investing Cash Flow(86.35M)(143.79M)(322.39M)(161.9M)(179.55M)
Debt Repayment(17.5M)(9.63M)37.75M447.31M(6.25M)
Common Stock Issued6.55M01.33M(1.91M)7.89M
Common Stock Repurchased0(75M)0(225M)(175M)
Dividends Paid00000
Other Financing Activities(4.8M)(15.74M)(922K)(111.58M)(5.1M)
Financing Cash Flow(15.75M)(100.36M)38.16M108.82M(178.46M)
Effect of Forex Changes(2.98M)(3.94M)(3.19M)(685K)3.46M
Net Change in Cash67.19M24.97M(105.67M)127.96M(61.32M)
Free Cash Flow75.75M162.87M143.63M142.45M260.44M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.